Dergiler / Biotech Studies / 2021 / Cilt: 30 - Sayı: 1

Potential biomarkers for lung adenocarcinoma identified by integrative transcriptomics analysis

Sayfa
33–42
Yayın Tarihi
2021-06-15
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Our findings suggested that identified biomarkers could be valuable in LUAD progression and they should be considered for further experimentation.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Lung cancer is one of the most occurring and death-causing cancers worldwide.
📊
Temel Bulgular & Veri:Despite the progress, survival rate is still low due to the late diagnosis.
💡
Sonuç & Katkı:Our findings suggested that identified biomarkers could be valuable in LUAD progression and they should be considered for further experimentation.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Lung adenocarcinoma · Transcriptome profiling · Network reconstruction

Abstract

Lung cancer is one of the most occurring and death-causing cancers worldwide. Despite the progress, survival rate is still low due to the late diagnosis. The aim of this study is to develop a computational framework to identify potential prognostic biomarkers for lung adenocarcinoma (LUAD). Gene expression profiles obtained from three independent studies were analyzed to find differentially expressed genes (DEGs) in LUAD. Disease-specific protein-protein interaction (PPI) network was constructed among common DEGs and hub proteins were identified. Gene expression data was integrated with the human transcriptional regulatory network (TRN) to identify key regulatory elements and construct disease-specific TRN. Hub proteins that were also present in TRN of LUAD were considered as potential biomarkers and assessed by survival analysis. AURKA, CAV1, CLU, ENO1, FHL1, FHL2, LMO2, MYH11, NME1 and SFN were discovered as biomarkers for LUAD and survival analysis not only indicated their significant prognostic performance as a group but also revealed their contribution to the discrimination of risk groups. Our findings suggested that identified biomarkers could be valuable in LUAD progression and they should be considered for further experimentation.

🔖

Bu Makaleye Atıf Yap

KASAVİ, C. (2021). Potential biomarkers for lung adenocarcinoma identified by integrative transcriptomics analysis. Biotech Studies, Cilt: 30 - Sayı: 1, 33–42. https://ajindex.com/articles/476422

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. guirre-Gamboa, R., Gomez-Rueda, H., Martínez-Ledesma, E., Martínez-Torteya, A., Chacolla-Huaringa, R., Rodriguez-Barrientos, A., Tamez-Peña, J. G., & Treviño, V. (2013). SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis. PLoS ONE, 8(9), 1–9. https://doi.org/10.1371/journal.pone.0074250
  2. Benjamini, Y., & Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological), 57(1), 289–300.
  3. Bolstad, B. M., Irizarry, R. A., Astrand, M., & Speed, T. P. (2003). A Comparison of Normalization Methods for High Density Oligonucleotide Array Data based on Variance and Bias. Bioinformatics, 19(2), 185–193. http://www.ncbi.nlm.nih.gov/pubmed/12538238
  4. Bovolenta, L. A., Acencio, M. L., & Lemke, N. (2012). HTRIdb: an open-access database for experimentally verified human transcriptional regulation interactions. BMC Genomics, 13(405). https://doi.org/10.1186/1471-2164-13-405
  5. Cagle, P. T., Allen, T. C., & Olsen, R. J. (2013). Lung cancer biomarkers: present status and future developments. Archives of Pathology & Laboratory Medicine, 137(9), 1191–1198. https://doi.org/10.5858/arpa.2013-0319-CR
  6. Cao, C. Y., Mok, S. W.-F., Cheng, V. W.-S., & Tsui, S. K.-W. (2015). The FHL2 Regulation in the Transcriptional Circuity of Human Cancers. Gene, 572(1), 139–148. https://doi.org/10.1016/j.physbeh.2017.03.040
  7. Chin, C. H., Chen, S. H., Wu, H. H., Ho, C. W., Ko, M. T., & Lin, C. Y. (2014). cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Systems Biology, 8 (Suppl 4(511), 1–7. https://doi.org/10.1186/1752-0509-8-S4-S11
  8. Chou, C. H., Shrestha, S., Yang, C. D., Chang, N. W., Lin, Y. L., Liao, K. W., Huang, W. C., Sun, T. H., Tu, S. J., Lee, W. H., Chiew, M. Y., Tai, C. S., Wei, T. Y., Tsai, T. R., Huang, H. T., Wang, C. Y., Wu, H. Y., Ho, S. Y., Chen, P. R., … & Huang, H. Da. (2018). MiRTarBase update 2018: A resource for experimentally validated microRNA-target interactions. Nucleic Acids Research, 46(D1), D296–D302. https://doi.org/10.1093/nar/gkx1067 Cieślik, M., & Chinnaiyan, A. M. (2018). Cancer transcriptome profiling at the juncture of clinical translation. Nature Reviews Genetics, 19(2), 93–109. https://doi.org/10.1038/nrg.2017.96
  9. Ding, L., Wang, Z., Yan, J., Yang, X., Liu, A., Qiu, W., Zhu, J., Han, J., Zhang, H., Lin, J., Cheng, L., Qin, X., Niu, C., Yuan, B., Wang, X., Zhu